Search results for "complication"

showing 10 items of 2051 documents

Predictive Factors of Response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs): A Multi-Institutional Study

2019

Imatinib 400 mg is the standard of care for medical treatment of advanced GISTs. In the majority of cases, however, GISTs eventually develop resistance to imatinib. The optimal second line treatment has not been established yet and imatinib dose escalation (800 mg) or sunitinib represent two feasible options. The objective of this retrospective, multi-institutional, study is to analyze the validity of several parameters as possible predictive factors of response to sunitinib after imatinib failure. We reviewed 128 metastatic GISTs treated with sunitinib between January 2007 to June 2017. Primary tumour site, metastatic site, c-KIT/PDGFR-α mutational status, PET-FDG status and type…

GiSTSunitinibbusiness.industryImatinibmedicine.diseaseurologic and male genital diseasesImatinib resistantdigestive system diseasesfemale genital diseases and pregnancy complicationsmedicineCancer researchGastrointestinal stromal tumors (GISTs)businessneoplasmsmedicine.drugoncology_oncogenics
researchProduct

An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience

2020

Diabetes and cancer frequently coexist in the same subject, often with relevant clinical effects on the management and prognosis of the comorbid patient. The existing guidelines, however, do not appropriately address many clinical issues in this setting. Although collaboration between diabetologists and oncologists should play an important role in achieving appropriate levels of care, close coordination or agreement between these specialists is seldom offered. There is an urgent need for greater interdisciplinary integration between all specialists involved in this setting, for a shared approach ensuring that organisational silos are overcome. To this end, the Italian Associations of Medica…

Glucose controlHospital settingSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismMedical OncologyDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyClinical pathwayClinical pathwaysClinical pathwayDiabetes mellitusNeoplasmsInternal MedicineMedicineHumans030212 general & internal medicineInpatient diabetes careDiabetes and cancerbusiness.industryDelivery of Health Care IntegratedCancerGeneral MedicineInpatient hyperglycaemiamedicine.diseasePrognosisIntegrated careItalyOncologyDischarge planningContinuity of careMedical emergencybusiness
researchProduct

Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us

2022

As the world enters its third year of the COVID-19 pandemic, individuals with diabetes have faced particular challenges from the virus. A deleterious bidirectional relationship exists between the two disorders, with heightened inflammatory, immunologic, and cellular mechanisms leading to a more severe illness and increased morbidity and mortality. Tight glucose control, though necessary, is hampered by physical restrictions and difficulty accessing health care. Novel glucose-lowering medications may provide unique benefits in this regard. It is imperative that multi-pronged efforts be prioritized in order to reduce adverse outcomes in patients with diabetes at risk for COVID-19.

GlucoseCOVID-19 cardiometabolic risk complications diabetes obesity treatmentSARS-CoV-2Endocrinology Diabetes and MetabolismDiabetes MellitusInternal MedicineCOVID-19HumansPandemicsMetabolic Syndrome and Related Disorders
researchProduct

Advanced Glycation End Products: Do They Impair Bone Health in Diabetes?

2022

AbstractIn diabetes mellitus (DM), there is increased formation and accumulation of advanced glycation end products (AGEs), which represent a heterogeneous class of molecules produced by non-enzymatic glycation of various molecules during long-term hyperglycaemia. Several studies have examined the role of AGEs in DM complications. Accumulating evidence suggests that AGEs affect bone metabolism. New knowledge indicates that they may play a role in bone disease among DM subjects. More data are now needed to clarify their role and to explore new AGEs-based therapeutic options for optimal bone health in DM.

Glycation End Products AdvancedDiabetes ComplicationsEndocrinologyBone Densityadvanced glycation end products bone formation complications diabetes mellitusEndocrinology Diabetes and MetabolismReceptor for Advanced Glycation End ProductsDiabetes MellitusInternal MedicineHumansGeneral Medicine
researchProduct

IMPROVEMENT IN REDOX HOMEOSTASIS AFTER CYTOREDUCTIVE SURGERY IN COLORECTAL ADENOCARCINOMA

2021

Colorectal cancer (CRC) as one the most common cancer type is associated with oxidative stress. Surgery is the only curative modality for early-stage CRC. The aim of this study was to evaluate the oxidative damage biomarkers as well as enzymatic and nonenzymatic antioxidants in patients with CRC before and after tumor resection and in healthy controls. 60 patients with stage I/II colorectal adenocarcinoma and 43 healthy controls were recruited in this study. We measured plasma levels of oxidative damage biomarkers, including advanced oxidation protein products (AOPP), advanced glycation end products (AGEs), malondialdehyde (MDA), and oxidized low-density lipoprotein (ox-LDL) at baseline and…

Glycation End Products AdvancedMale0301 basic medicineAgingAntioxidantColorectal cancermedicine.medical_treatmentmedicine.disease_causeBiochemistryGastroenterologychemistry.chemical_compoundPostoperative Complications0302 clinical medicineMalondialdehydeHomeostasischemistry.chemical_classificationbiologyGlutathione peroxidaseCytoreduction Surgical ProceduresGeneral MedicineMiddle AgedCatalaseMalondialdehydecolorectal cancer colorectal surgery cytoreductive surgery redox homeostasisLipoproteins LDLCatalase030220 oncology & carcinogenesisFemaleColorectal NeoplasmsResearch ArticleAdultmedicine.medical_specialtyArticle SubjectAdenocarcinomaSuperoxide dismutase03 medical and health sciencesInternal medicinemedicineHumansAgedGlutathione PeroxidaseQH573-671business.industryCell Biologymedicine.diseaseOxidative Stress030104 developmental biologychemistrybiology.proteinCytologybusinessOxidative stressLipoprotein
researchProduct

Advanced Glycation End Products: New Clinical and Molecular Perspectives

2021

Diabetes mellitus (DM) is considered one of the most massive epidemics of the twenty-first century due to its high mortality rates caused mainly due to its complications; therefore, the early identification of such complications becomes a race against time to establish a prompt diagnosis. The research of complications of DM over the years has allowed the development of numerous alternatives for diagnosis. Among these emerge the quantification of advanced glycation end products (AGEs) given their increased levels due to chronic hyperglycemia, while also being related to the induction of different stress-associated cellular responses and proinflammatory mechanisms involved in the progression …

Glycation End Products Advancedmedicine.medical_specialtyHealth Toxicology and Mutagenesis030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyFluorescence03 medical and health sciences0302 clinical medicineChronic hyperglycemiaGlycationDiabetes mellitusskin fluorescencemedicineHumansIntensive care medicineSkinbusiness.industryadvanced glycation end productsHigh mortalityPublic Health Environmental and Occupational HealthRmedicine.diseasechronic complicationsHyperglycemiadiabetes mellitusMedicinebusinessInternational Journal of Environmental Research and Public Health
researchProduct

The diabetic cataract: an unusual presentation in a young subject: case report.

1997

This case report concerns a 14-year-old female patient, whose insulin-dependent diabetes mellitus was displayed by one infrequent complication, the cataract. This is an unusual manifestation in a 14-year-old patient; indeed, there are many findings in experimental animals demonstrating the development of this complication by maintaining blood glucose levels above 12 mM. After surgical therapy, complete vision was recovered, but we think that an earlier diagnosis and therapy of metabolic derangement of diabetes may have avoided this complication.

GlycosuriaBlood Glucosemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismEye diseaseHypercholesterolemiaCataract ExtractionKetone BodiesCataractEndocrinologyGlycosuriaDiabetes mellitusFemale patientInternal MedicinemedicineHumansHypertriglyceridemiaMetabolic derangementbusiness.industrymedicine.diseaseDiabetic cataractSurgeryDiabetes Mellitus Type 1FemalePresentation (obstetrics)medicine.symptomComplicationbusinessJournal of diabetes and its complications
researchProduct

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial

2012

    In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in…

Graft RejectionCHRONIC KIDNEY-DISEASEMaleTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationKidneyKidney Function TestsGLOMERULAR-FILTRATION-RATEImmunosuppressive AgentHEPATOCELLULAR-CARCINOMASIROLIMUS-BASED IMMUNOSUPPRESSIONImmunology and AllergySirolimuPharmacology (medical)Prospective StudiestacrolimusMYCOPHENOLATE-MOFETILCOMPLICATIONSCross-Over Studiesliver transplantationwithdrawalGraft SurvivalCross-Over StudieMiddle AgedTreatment Outcomesurgical procedures operativeSurvival AnalysireducedLife Sciences & BiomedicineImmunosuppressive AgentsHumanGlomerular Filtration Ratemedicine.drugAdultmedicine.medical_specialtyRandomizationTime FactorAdolescentEfficacyUrologyRenal functionchemical and pharmacologic phenomenaCALCINEURIN INHIBITORRisk AssessmentDrug Administration ScheduleFollow-Up StudieYoung Adultstomatognathic systemTransplantation ImmunologyDOSE TACROLIMUSConfidence IntervalsmedicineHumansMETAANALYSISAgedSirolimusTransplantationKidney Function TestScience & TechnologyEverolimusDose-Response Relationship Drugbusiness.industryeverolimutacrolimuOriginal ArticleseverolimusSurvival AnalysisCrossover studyTacrolimusSurgeryTransplantationProspective StudieCONVERSIONstomatognathic diseasesSirolimusSurgerybusinessConfidence IntervalLiver FailureFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

A NONHEALING ULCER DIAGNOSED AS EXTRAMEDULLARY PLASMOCYTOMA OF THE LIMB EIGHT YEARS AFTER CARDIAC TRANSPLANTATION

1999

A 63-year-old man was hospitalized for a nonhealing ulcer of the left lower leg that appeared 8 years after orthotopic cardiac transplantation under immunosuppressive therapy including cyclosporine. Serum protein electrophoresis, immunofixation, and urinalysis revealed a monoclonal gammopathy IgG kappa. The final diagnosis of an extramedullary plasmocytoma was made by biopsy of the ulcer, which showed formations of plasmablastic cells. We report a rare case of extramedullary plasmocytoma as a posttransplantational malignancy.

Graft RejectionMaleImmunofixationmedicine.medical_specialtySkin NeoplasmsUrinalysisMalignancyBiopsymedicineHumansTransplantationmedicine.diagnostic_testbiologybusiness.industryLeg UlcerMiddle Agedmedicine.diseaseSurgeryTransplantationHematopoiesis ExtramedullarySerum protein electrophoresisCyclosporinebiology.proteinHeart TransplantationPlasmacytomabusinessComplicationImmunosuppressive AgentsPlasmacytomaTransplantation
researchProduct

Postoperative Repositioning of Inverted Descemet Membrane Endothelial Keratoplasty Grafts

2019

Item does not contain fulltext PURPOSE: To present 4 cases of postoperative repositioning of inverted grafts after Descemet membrane endothelial keratoplasty (DMEK). METHODS: Retrospective case reports of 4 patients presenting with subtotal to total graft detachment after DMEK, most probably owing to upside-down graft positioning. Graft repositioning was performed 1 to 14 days after initial DMEK surgery. In 3 cases (cases 1, 3, and 4), repositioning was performed without removing the graft from the anterior chamber (AC), whereas for case 2, the graft had to be removed from the AC to attain correct graft orientation. RESULTS: In all 4 cases, the initially upside-down DMEK grafts could be suc…

Graft RejectionMaleReoperationmedicine.medical_specialtyDescemet membraneClear corneasSensory disorders Donders Center for Medical Neuroscience [Radboudumc 12]Corneal Diseases03 medical and health sciences0302 clinical medicinePostoperative ComplicationsCorneal edemaOphthalmologyCorneamedicineHumansDescemet MembraneAgedRetrospective StudiesAged 80 and overbusiness.industryMiddle AgedEndothelial cell densityOphthalmologymedicine.anatomical_structuresurgical procedures operative030221 ophthalmology & optometryFemalebusiness030217 neurology & neurosurgeryDescemet Stripping Endothelial KeratoplastyCornea. the Journal of Cornea and External Disease
researchProduct